Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Interest Expenses (2020 - 2021)

Foghorn Therapeutics has reported Interest Expenses over the past 2 years, most recently at $426000.0 for Q4 2021.

  • Quarterly results put Interest Expenses at $426000.0 for Q4 2021, up 32.71% from a year ago — trailing twelve months through Sep 2022 was $426000.0 (down 76.35% YoY), and the annual figure for FY2021 was $1.9 million, up 94.69%.
  • Interest Expenses for Q4 2021 was $426000.0 at Foghorn Therapeutics, down from $499000.0 in the prior quarter.
  • Over the last five years, Interest Expenses for FHTX hit a ceiling of $499000.0 in Q3 2021 and a floor of $198000.0 in Q2 2020.